Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 7, 2026Advanced Composites and Hybrid MaterialsOpen Access

Harnessing engineered bacteria for revolutionizing cancer immunotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

KZKan ZhouLCLei‐Ming CaoHLHan-Yue Luo

Discussion

Loading...

Member takes

Overview

This review discusses engineered bacteria's role in enhancing cancer immunotherapy and their therapeutic applications, highlighting ongoing challenges.

Key Points

  • The aim is to summarize advances in engineered bacteria and their therapeutic applications in cancer immunotherapy.
  • Reviewed literature on genetically engineered bacteria for cancer treatment.
  • Analyzed the role of bacteria in tumor dynamics and therapeutic responses.
  • Examined mechanisms of engineered bacteria in immunotherapy and drug delivery.
  • Engineered bacteria demonstrated direct anti-tumor effects.
  • Promising applications in enhancing existing immunotherapies.
  • Potential for use in drug delivery systems and cancer vaccination strategies.

Cite This Study

Zhou et al. (2026) studied this question.

synapsesocial.com/papers/69abc0b85af8044f7a4e972dhttps://doi.org/10.1007/s42114-026-01664-3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Coating Dormant Collagenase‐Producing Bacteria with Metal‐Anesthetic Networks for Precision Tumor Therapy2024 · 3 citations
  2. 2Development of a TNF-α-mediated Trojan Horse for bacteria-based cancer therapy2022 · 31 citations
  3. 3Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study2016 · 860 citations
  4. 4Intravenous Delivery of Living <i>Listeria monocytogenes</i> Elicits Gasdmermin-Dependent Tumor Pyroptosis and Motivates Anti-Tumor Immune Response2022 · 116 citations